AI 9250US

Sheet

PTO/SB/08A (10-98
Approved for use through 10/31/99. OMB 0651-0331
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE 0 8 2005 tion Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number stitute for form 1449A/PTO Complete if Known Application Number 10/541,526 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) July 7, 2005 Filing Date First Named Inventor Stephen Robert Bloom Group Art Unit 1646

> Examiner Name Attorney Docket Number

			U.S. PATENT DOCL	IMENTS	
Examiner Initials*	Cite No.1	US Patent Docur	of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
			Code ² known)		
ADK		5,026,685	Boublik, et al.	06-25-1991	
		5,574,010	McFadden	11-12-1996	
		5,604,203	Balasubramaniam	02-18-1997	
		5,696,093	Tseng, et al.	12-09-1997	
		6,046,167	Balasubramaniam	04-04-2000	
		6,191,102	DiMarchi, et al.	02-20-2001	
V		6,608,098	Nagase, et al.	08-19-2003	
ADK		6,620,910	Calas, et al.	09-16-2003	
-					
	·				

				,	OREIGN PATENT DOCUMENT	S		
Examiner Initials*	Cite No.1		Foreign Patent Doc	ument	Applicant of Cited Document Ci	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1ª
		Office.	Number*	Kind Code ⁵ (if known)				
ADK			0 619 332		Kuraray Co., Ltd.	10-12-1994		
			0 795 562		Kyowa Hakko Kogyo Co., Ltd.	09-17-1997		
		<u> </u>	WO 93/19175		Thorens Bernard	09-30-1993	\	\vdash
			WO 99/43707		Novo Nordisk A/S	09-02-1999		
			WO 00/42026		Novonordisk AS and Agouron Pharma	07-20-2000		
ADK]	WO 00/59887		Neurogen Corporation	10-12-2000		

Examiner's	Date Considered	
Signature	 	•

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant to place a check mark here if English language Translation is attached.

+

Please type a plus size (-) inside this box ->

PTO/SB08A (10-98 Approved for use through 10/31/99. OM8 0851-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number itute for form 1449A/PTO Complete if Known 10/541,526 **Application Number** INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Filing Date July 7, 2005 First Named Inventor Stephen Robert Bloom Group Art Unit **Examiner Name** Attorney Docket Number AI 9250US Sheet

				F	OREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1		Foreign Patent Document		Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	٠	Office.	Number ⁴	Kind Code ⁵ (if known)		'		
ADK			WO 00/78333		Eli Lilly & Co.	12-28-2000		
		1	WO 01/04156		Zealand Pharmaceuticals	01-18-2001		
			WO 01/14368		Viropharma Incorporated	03-01-2001		
			WO 01/35988		Novo Nordisk A/S	05-25-2001		
		1	WO 01/66135		Novo Nordisk A/S	09-13-2001		
			WO 01/89554		Bionebraska, Inc. and & Sankyo Company, Ltd	11-29-2001		
			WO 02/03978		Metabasis Therapeutics, Inc.	01-17-02		
			WO 02/66479		Banyu Pharmaceutical Co., Ltd	08-29-2002		
V			WO 02/67918	·	Banyu Pharmaceutical Co., Ltd	09-06-2002		
AĎK			WO 03/022304		IC Innovations	03-20-2003		
		-				 		-
	·							
		 				· · · · · · · · · · · · · · · · · · ·		ļ
		-		- 	· · · · · · · · · · · · · · · · · · ·			ļ
				- 	 	 		
		 				 	<u> </u>	┼─
						<u> </u>	· · · · · · · · · · · · · · · · · · ·	

OTHER ART - NON PATENT LITERATURE DOCUMENTS							
Examiner's Signature			Date Considered				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

45060805v1

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

NOV 0 8 2005 fuction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control numb Substitute for form 1449A/PTO Complete if Known Application Number 10/541,526 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Filing Date July 7, 2005 First Named Inventor Stephen Robert Bloom Group Art Unit 1646 Examiner Name Attorney Docket Number Sheet of AI 9250US

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, joumal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Τ²					
ADK		ADRIAN, et al., "Effect of peptide YY on gastric, pancreatic, and biliary function in humans," Gastroenterology, 89:494 499 (1985).						
		CUMMINGS, et al., "A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans", <i>Diabetes</i> , 50:1714- 1719 (2001).						
		DAKIN, et al., "Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats", Am J Physiol Endocrinol Metab., 283(6):E1173-7 (2002).	•					
		DAKIN, et al, "Oxyntomodulin inhibits food intake in the rat", Endocrinilogy, 142:4244-4250 (2001).						
		ENG, et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas", <i>J Biol Chem</i> , 267:7402-7405 (1992).						
		ENGLISH, "Food fails to suppress ghrelin levels in obese humans", J Clin Endocrinol Metab, 87:2984-87 (2002).						
		GHATEI, et al., "Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract", <i>J Clin Endocrinol Metab</i> , 57:488-495 (1983).						
		KREYMANN, "Glucagon-like peptide-1 7-36: a physiological incretin in man", Lancet, 2:1300-1304 (1987).						
		TATEMOTO, "Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion", <i>Proc. Natl. Acad. Sci.</i> , 79:2514-8 (1982).						
		UESAKA, et al., "Glucagon-like peptide isolated from the eel intestine: effects on atrial beating", <i>J Exp Biol.</i> , 204(Pt 17):3019-26 (2001).						
		WREN, et al., "Ghrelin enhances appetite and increases food intake in humans", J Clin Endocrinol Metab, 86:5992-5 (2001).						
ADK		WYNNE, et al., "Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial", <i>Diabetes</i> , 54(8):2390-5 (2005).						

Examiner's Date Considered	00/07/0007
Signature /Andrew D. Kosar/	02/07/2007

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

MAR. 20.-2006 10:56AM

PABST PATENT GROUP

RECEIVED CENTRAL FAX CENTER

NO. 7336 P. 6

Please type a plus eigh	(4) inside this box →			MAR 20	2006	PTO/SBRIA (10-65 Approved for use Brough 10/31/80, Oxeo Osci-Docti- Patent and Tradomark Office: U.S. DEPARTMENT OF CONMICENCE	
Under the Preparent Reduction Accest 1993, no persons are required to respond to a collection of information unless it contains a valid CDMI control number							
Sub	slitute for form 144	9A/PTO					
					Com	plete if Known	

Substitute for form 1449A/PTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/541,526	
	Filing Date	July 7, 2005	
	First Named Inventor	Stephen Robert Bloom	
	Group Art Unit	1846	
•	Examiner Name		
Sheet 1 of 1	Attorney Docket Number	Al 9250US	

	U.S. PATENT DOCUMENTS								
Examiner Inibals*	Cite No. ¹	US Patent Doourn Number Kind C		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passagas or Relevant Figures Appear			
ADK		6,583,111		DiMarchi, et at	06-24-2003				
ADK		2004/0018975		DiMarchi, et al	01-29-2004				
				· · · · · · · · · · · · · · · · · · ·					
·									

				F	OREIGN PATENT DOCUMEN	TS			
Examiner Initals*	Clie No.1		F	oreign Patent Doc	ument	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1,8
		Office.3	Number	Kind Code ² (If known)		, , , , ,	rigula Appea		
		<u> </u>							
				1					
							•		
								T	
	l								
		1 1		l J		1			

Examiner's Signature	/Andrew D. Kosar/	Date Considered 02/07/2007

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Tradement Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Petent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not classon is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emparor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.